Hematopoietic stem cell transplantation: An overview of infection risks and epidemiology

Infectious Disease Clinics of North America

Volumn 24, Issue 2, 2010, Pages 257-272

  Wingard, John R ^a   Hsu, Jack ^a   Hiemenz, John W ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

GVHD; Hematopoietic stem cell transplantation; Opportunistic infections

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; FLUDARABINE; PENTOSTATIN; THYMOCYTE ANTIBODY;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; BONE MARROW DEPRESSION; CANCER CHEMOTHERAPY; CHRONIC GRAFT VERSUS HOST DISEASE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; EPIDEMIOLOGICAL DATA; FEBRILE NEUTROPENIA; FEVER; HEMATOLOGIC MALIGNANCY; HEPATITIS; HOST RESISTANCE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION PREVENTION; INFECTION RISK; INNATE IMMUNITY; LUNG INFILTRATE; MALIGNANT NEOPLASTIC DISEASE; MICROORGANISM; MYCOSIS; NEUTROPENIA; NONHUMAN; PATHOGENESIS; PNEUMONIA; RASH; REVIEW; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION; WHOLE BODY RADIATION;

COMMUNICABLE DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; RISK FACTORS;

EID: 77952679733     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2010.01.010     Document Type: Review

References (54)

1. Tomblyn M., Chiller T., Einsele H., et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Bone Marrow Transplant 2009, 15(10):1143-1238.
2. Ljungman P., Engelhard D., Da La Camara R., et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant 2005, 35:737-746.
3. Hughes W.T., Armstrong D., Bodey G.P., et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002, 34(6):730-751.
4. Friefeld AG, Baden LR, Brown AE, et al. The NCCN fever and neutropenia clinical practice guidelines in oncology. Version 1. 2005.
5. Gosselin M.V., Adams R.H. Pulmonary complications in bone marrow transplantation. J Thorac Imaging 2002, 17(2):132-144.
6. Heussel C.P., Kauczor H.U., Heussel G., et al. Early detection of pneumonia in febrile neutropenic patients: use of thin-section CT. AJR Am J Roentgenol 1997, 169(5):1347-1353.
7. Conces D.J. Noninfectious lung disease in immunocompromised patients. J Thorac Imaging 1999, 14(1):9-24.
8. Wingard J.R., Mellits E.D., Sostrin M.B., et al. Interstitial pneumonitis after allogeneic bone marrow transplantation: nine-year experience at a single institution. Medicine (Baltimore) 1988, 67(3):175-186.
9. Wingard J.R., Piantadosi S., Burns W.H., et al. Cytomegalovirus infections in bone marrow transplant recipients given intensive cytoreductive therapy. Rev Infect Dis 1990, 12(Suppl 7):S793-S804.
10. Harrington R.D., Hooton T.M., Hackman R.C., et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis 1992, 165(6):987-993.
11. Ljungman P. Respiratory virus infections in bone marrow transplant recipients: the European perspective. Am J Med 1997, 102(3A):44-47.
12. Whimbey E., Champlin R.E., Couch R.B., et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis 1996, 22(5):778-782.
13. Whimbey E., Englund J.A., Couch R.B. Community respiratory virus infections in immunocompromised patients with cancer. Am J Med 1997, 102(3A):10-18.
14. Bowden R.A. Respiratory virus infections after marrow transplant: the Fred Hutchinson Cancer Research Center experience. Am J Med 1997, 102(3A):27-30.
15. Nichols W.G., Gooley T., Boeckh M. Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience. Biol Blood Marrow Transplant 2001, 7(Suppl):11S-15S.
16. Whimbey E., Vartivarian S.E., Champlin R.E., et al. Parainfluenza virus infection in adult bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis 1993, 12(9):699-701.
17. Ljungman P. Respiratory virus infections in stem cell transplant patients: the European experience. Biol Blood Marrow Transplant 2001, 7(Suppl):5S-7S.
18. De La Rosa G.R., Champlin R.E., Kontoyiannis D.P. Risk factors for the development of invasive fungal infections in allogeneic blood and marrow transplant recipients. Transpl Infect Dis 2002, 4(1):3-9.
19. Fukuda T., Boeckh M., Carter R.A., et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003, 102(3):827-833.
20. Greene R.E., Schlamm H.T., Oestmann J.W., et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007, 44(3):373-379.
21. Chamilos G., Marom E.M., Lewis R.E., et al. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 2005, 41(1):60-66.
22. Wingard J.R., Santos G.W., Saral R. Late-onset interstitial pneumonia following allergenic bone marrow transplantation. Transplantation 1985, 39(1):21-23.
23. Marr K.A., Carter R.A., Boeckh M., et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002, 100(13):4358-4366.
24. Yamasaki S., Heike Y., Mori S., et al. Infectious complications in chronic graft-versus-host disease: a retrospective study of 145 recipients of allogeneic hematopoietic stem cell transplantation with reduced- and conventional-intensity conditioning regimens. Transpl Infect Dis 2008, 10:252-259.
25. Daly A.S., McGeer A., Lipton J.H. Systemic nocardiosis following allogeneic bone marrow transplantation. Transpl Infect Dis 2003, 5:16-20.
26. Boeckh M., Leisenring W., Riddell S.R., et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003, 101(2):407-414.
27. Dunagan D.P., Baker A.M., Hurd D.D., et al. Bronchoscopic evaluation of pulmonary infiltrates following bone marrow transplantation. Chest 1997, 111(1):135-141.
28. Feller-Kopman D., Ernst A. The role of bronchoalveolar lavage in the immunocompromised host. Semin Respir Infect 2003, 18(2):87-94.
29. Maertens J., Theunissen K., Verhoef G., et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005, 41(9):1242-1250.
30. Maertens J., Van Eldere J., Verhaegen J., et al. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 2002, 186(9):1297-1306.
31. Pfeiffer C.D., Fine J.P., Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006, 42:1417-1427.
32. Gorschluter M., Mey U., Strehl J., et al. Neutropenic enterocolitis in adults: systematic analysis of evidence quality. Eur J Haematol 2005, 75(1):1-13.
33. Cardona A.F., Ramos P.L., Casasbuenas A. From case reports to systematic reviews in neutropenic enterocolitis. Eur J Haematol 2005, 75(5):445-446.
34. Aksoy D.Y., Tanriover M.D., Uzun O., et al. Diarrhea in neutropenic patients: a prospective cohort study with emphasis on neutropenic enterocolitis. Ann Oncol 2007, 18(1):183-189.
35. Cardona Zorrilla A.F., Reveiz H.L., Casasbuenas A., et al. Systematic review of case reports concerning adults suffering from neutropenic enterocolitis. Clin Transl Oncol 2006, 8(1):31-38.
36. Gorschluter M., Mey U., Strehl J., et al. Invasive fungal infections in neutropenic enterocolitis: a systematic analysis of pathogens, incidence, treatment and mortality in adult patients. BMC Infect Dis 2006, 6:35.
37. Weiss K. Poor infection control, not fluoroquinolones, likely to be primary cause of Clostridium difficile-associated diarrhea outbreaks in Quebec. Clin Infect Dis 2006, 42(5):725-727.
38. McDonald L.C., Killgore G.E., Thompson A., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005, 353(23):2433-2441.
39. Pepin J., Saheb N., Coulombe M.A., et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005, 41(9):1254-1260.
40. Kuijper E.J., van den Berg R.J., Debast S., et al. Clostridium difficile ribotype 027, toxinotype III, the Netherlands. Emerg Infect Dis 2006, 12(5):827-830.
41. Loo V.G., Poirier L., Miller M.A., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005, 353(23):2442-2449.
42. Yolken R.H., Bishop C.A., Townsend T.R., et al. Infectious gastroenteritis in bone-marrow-transplant recipients. N Engl J Med 1982, 306(17):1010-1012.
43. Townsend T.R., Bolyard E.A., Yolken R.H., et al. Outbreak of coxsackie A1 gastroenteritis: a complication of bone-marrow transplantation. Lancet 1982, 1(8276):820-823.
44. Cox G.J., Matsui S.M., Lo R.S., et al. Etiology and outcome of diarrhea after marrow transplantation: a prospective study. Gastroenterology 1994, 107(5):1398-1407.
45. van Kraaij M.G., Dekker A.W., Verdonck L.F., et al. Infectious gastro-enteritis: an uncommon cause of diarrhoea in adult allogeneic and autologous stem cell transplant recipients. Bone Marrow Transplant 2000, 26(3):299-303.
46. La Rosa A.M., Champlin R.E., Mirza N., et al. Adenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis 2001, 32(6):871-876.
47. Shields A.F., Hackman R.C., Fife K.H., et al. Adenovirus infections in patients undergoing bone-marrow transplantation. N Engl J Med 1985, 312(9):529-533.
48. Hale G.A., Heslop H.E., Krance R.A., et al. Adenovirus infection after pediatric bone marrow transplantation. Bone Marrow Transplant 1999, 23(3):277-282.
49. Boeckh M., Nichols W.G., Papanicolaou G., et al. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003, 9(9):543-558.
50. Boeckh M., Nichols W.G. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004, 103(6):2003-2008.
51. Dykewicz C.A., Jaffe H.W., Spira T.J., et al. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000, 49(RR-10):1-125.
52. Walsh T.J., Anaissie E.J., Denning D.W., et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008, 46(3):327-360.
53. Pappas P.G., Rex J.H., Sobel J.D., et al. Infectious Diseases Society of America. Guidelines for treatment of candidiasis. Clin Infect Dis 2004, 38(2):161-189.
54. Boeckh M., Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009, 113(23):5711-5719.